Inactive Instrument

Phytopharm plc Stock London S.E.

Equities

GB0006869720

Biotechnology & Medical Research

End-of-day quote London S.E.
- GBX - Intraday chart for Phytopharm plc

Financials

Sales 2024 * 5.2M 6.64M 9.05M Sales 2025 * - Capitalization 3.38M 4.32M 5.89M
Net income 2024 * -2M -2.56M -3.48M Net income 2025 * - EV / Sales 2024 * 0.38 x
Net cash position 2024 * 1.4M 1.79M 2.44M Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.27 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.17%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 63 17-02-05
Director of Finance/CFO 47 19-05-30
Chairman 59 13-10-13
Members of the board TitleAgeSince
Chairman 59 13-10-13
Director/Board Member 49 16-09-15
Director/Board Member 60 23-10-04
More insiders
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
More about the company